Expression and Prognostic Value of Glucose Transporter 3 in Diffuse Large B Cell Lymphoma

References

• Kallam A, Adusumalli J, Armitage JO. Surveillance in patients with diffuse large B cell lymphoma. Mayo Clin Proc. 2020;95(1):157–163. doi:10.1016/j.mayocp.2019.05.011
   PubMed Web of Science ®Google Scholar
• Frontzek F, Lenz G. Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev Clin Pharmacol. 2019;12(11):1059–1067. doi:10.1080/17512433.2019.1683447
   PubMed Web of Science ®Google Scholar
• Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020;52(1):53–67. doi:10.1016/j.pathol.2019.08.013
   PubMed Web of Science ®Google Scholar
• Sewastianik T, Szydlowski M, Jablonska E, et al. FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. Oncogene. 2016;35(46):5989–6000. doi:10.1038/onc.2016.126
   PubMed Web of Science ®Google Scholar
• Buppajarntham S, Junpaparp P, Kue APP. Warburg effect associated with transformed lymphoplasmacytic lymphoma to diffuse large B-cell lymphoma. Am J Emerg Med. 2013;31(6):999–e5. doi:10.1016/j.ajem.2013.01.038
   Web of Science ®Google Scholar
• Caro P, Kishan AU, Norberg E, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22(4):547–560. doi:10.1016/j.ccr.2012.08.014
   PubMed Web of Science ®Google Scholar
• Chiche J, Pommier S, Beneteau M, et al. GAPDH enhances the aggressiveness and the vascularization of non-Hodgkin’s B lymphomas via NF-κB-dependent induction of HIF-1α. Leukemia. 2015;29(5):1163–1176. doi:10.1038/leu.2014.324
   PubMed Web of Science ®Google Scholar
• Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863–875. doi:10.1016/j.tcb.2017.06.003
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006
   PubMed Web of Science ®Google Scholar
• Li W, Xu M, Li Y, et al. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer. J Transl Med. 2020;18(1):92. doi:10.1186/s12967-020-02267-2
   PubMed Web of Science ®Google Scholar
• Cascone T, McKenzie JA, Mbofung RM, et al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. 2018;27(5):977–987.e974. doi:10.1016/j.cmet.2018.02.024
   PubMed Web of Science ®Google Scholar
• Lizak B, Szarka A, Kim Y, et al. Glucose transport and transporters in the endomembranes. Int J Mol Sci. 2019;20(23):5898. doi:10.3390/ijms20235898
   PubMed Web of Science ®Google Scholar
• Koch H, Weber YG. The glucose transporter type 1 (Glut1) syndromes. Epilepsy Behav. 2019;91:90–93. doi:10.1016/j.yebeh.2018.06.010
   PubMed Web of Science ®Google Scholar
• Kuo CC, Ling HH, Chiang MC, et al. Metastatic colorectal cancer rewrites metabolic program through a Glut3-YAP-dependent signaling circuit. Theranostics. 2019;9(9):2526–2540. doi:10.7150/thno.32915
   PubMed Web of Science ®Google Scholar
• Massari F, Ciccarese C, Santoni M, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46–57. doi:10.1016/j.ctrv.2016.03.005
   PubMed Web of Science ®Google Scholar
• Gao H, Hao Y, Zhou X, et al. Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncol Lett. 2020;19(1):691–699. doi:10.3892/ol.2019.11191
   PubMedGoogle Scholar
• Masin M, Vazquez J, Rossi S, et al. GLUT3 is induced during epithelial-mesenchymal transition and promotes tumor cell proliferation in non-small cell lung cancer. Cancer Metab. 2014;2:11. doi:10.1186/2049-3002-2-11
   PubMedGoogle Scholar
• Friedberg JW. New strategies in diffuse large B-cell lymphoma: translating findings from gene expression analyses into clinical practice. Clin Cancer Res. 2011;17(19):6112–6117. doi:10.1158/1078-0432.CCR-11-1073
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–994. doi:10.1056/NEJM199309303291402
   PubMed Web of Science ®Google Scholar
• Wang J, Gao K, Lei W, et al. Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes. Oncotarget. 2017;8(3):5414–5425. doi:10.18632/oncotarget.14289
   PubMedGoogle Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–D995. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• King RL, Goodlad JR, Calaminici M, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Archiv. 2019;476:647–665.
   PubMed Web of Science ®Google Scholar
• de la Cruz-lopez KG, Castro-Munoz LJ, Reyes-Hernandez DO, Garcia-Carranca A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143. doi:10.3389/fonc.2019.01143
   PubMed Web of Science ®Google Scholar
• Reckzeh ES, Waldmann H. Small-molecule inhibition of glucose transporters GLUT-1-4. Chembiochem. 2019;21(1–2):45–52. doi:10.1002/cbic.201900544
   PubMed Web of Science ®Google Scholar
• Ceballos J, Schwalfenberg M, Karageorgis G, et al. Synthesis of indomorphan pseudo-natural product inhibitors of glucose transporters GLUT-1 and −3. Angewandte Chemie. 2019;58(47):17016–17025. doi:10.1002/anie.201909518
   Google Scholar
• Kuang R, Jahangiri A, Mascharak S, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017;2(2):e88815. doi:10.1172/jci.insight.88815
   PubMed Web of Science ®Google Scholar
• Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9(9):1084–1101. doi:10.2174/138955709788922610
   PubMed Web of Science ®Google Scholar
• Holman GD. Chemical biology probes of mammalian GLUT structure and function. Biochem J. 2018;475(22):3511–3534. doi:10.1042/BCJ20170677
   PubMed Web of Science ®Google Scholar
• Ancey PB, Contat C, Meylan E. Glucose transporters in cancer - from tumor cells to the tumor microenvironment. FEBS J. 2018;285(16):2926–2943. doi:10.1111/febs.14577
   PubMed Web of Science ®Google Scholar
• Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: are they a new feature to characterize carcinomas? Int J Cancer. 2018;142(12):2414–2424. doi:10.1002/ijc.31165
   PubMed Web of Science ®Google Scholar
• Labak CM, Wang PY, Arora R, et al. Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment. Am J Cancer Res. 2016;6(8):1599–1608.
   PubMed Web of Science ®Google Scholar
• Patching SG. Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol. 2017;54(2):1046–1077. doi:10.1007/s12035-015-9672-6
   PubMed Web of Science ®Google Scholar
• Kobliakov VA. The mechanisms of regulation of aerobic glycolysis (Warburg Effect) by oncoproteins in carcinogenesis. Biochemistry. 2019;84(10):1117–1128. doi:10.1134/S0006297919100018
   PubMed Web of Science ®Google Scholar
• Abbaszadeh Z, Cesmeli S, Biray Avci C. Crucial players in glycolysis: cancer progress. Gene. 2020;726:144158. doi:10.1016/j.gene.2019.144158
   PubMed Web of Science ®Google Scholar
• Noguera R, Burgos-Panadero R, Gamero-Sandemetrio E, de la Cruz-merino L, Alvaro Naranjo T. [An integral view of cancer (II). Fields of investigation and emerging biomarkers]. Revista Española de Patologia. 2019;52(4):222–233. Spanish. doi:10.1016/j.patol.2019.04.005
   Google Scholar
• Yu T, Wang Y, Fan Y, et al. CircRNAs in cancer metabolism: a review. J Hematol Oncol. 2019;12(1):90. doi:10.1186/s13045-019-0776-8
   PubMed Web of Science ®Google Scholar
• Hossain F, Andreana PR. Developments in carbohydrate-based cancer therapeutics. Pharmaceuticals. 2019;12(2). doi:10.3390/ph12020084
   Web of Science ®Google Scholar
• Qureshi AS, Ali S. Review: Warburg effect and renal cancer caused by errs in fumarate hydratase encoding gene. Pak J Pharm Sci. 2019;32(2):743–749.
   PubMed Web of Science ®Google Scholar
• Moriyama H, Moriyama M, Ozawa T, et al. Notch signaling enhances stemness by regulating metabolic pathways through modifying p53, NF-κB, and HIF-1α. Stem Cells Dev. 2018;27(13):935–947. doi:10.1089/scd.2017.0260
   PubMed Web of Science ®Google Scholar
• Yan YE, Zhang J, Wang K, et al. Significant reduction of the GLUT3 level, but not GLUT1 level, was observed in the brain tissues of several scrapie experimental animals and scrapie-infected cell lines. Mol Neurobiol. 2014;49(2):991–1004. doi:10.1007/s12035-013-8574-8
   PubMed Web of Science ®Google Scholar
• Zha X, Hu Z, Ji S, et al. NFkappaB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth. Cancer Lett. 2015;359(1):97–106. doi:10.1016/j.canlet.2015.01.001
   PubMed Web of Science ®Google Scholar
• Wang Y, Wu S, Huang C, Li Y, Zhao H, Kasim V. Yin Yang 1 promotes the Warburg effect and tumorigenesis via glucose transporter GLUT3. Cancer Sci. 2018;109(8):2423–2434. doi:10.1111/cas.13662
   PubMed Web of Science ®Google Scholar
• Brito AF, Abrantes AM, Ribeiro M, et al. Fluorine-18 fluorodeoxyglucose uptake in hepatocellular carcinoma: correlation with glucose transporters and p53 expression. J Clin Exp Hepatol. 2015;5(3):183–189. doi:10.1016/j.jceh.2015.05.003
   PubMedGoogle Scholar
• Watanabe M, Abe N, Oshikiri Y, Stanbridge EJ, Kitagawa T. Selective growth inhibition by glycogen synthase kinase-3 inhibitors in tumorigenic HeLa hybrid cells is mediated through NF-κB-dependent GLUT3 expression. Oncogenesis. 2012;1:e21. doi:10.1038/oncsis.2012.21
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Zhao J, Xu X, Bi L. Downregulation of GLUT3 promotes apoptosis and chemosensitivity of acute myeloid leukemia cells via EGFR signaling. Arch Iran Med. 2018;21(2):73–78.
   PubMed Web of Science ®Google Scholar
• Nie M, Yang L, Bi X, et al. Neutrophil extracellular traps induced by IL8 promote diffuse large B-cell lymphoma progression via the TLR9 signaling. Clin Cancer Res. 2019;25(6):1867–1879. doi:10.1158/1078-0432.CCR-18-1226
   PubMed Web of Science ®Google Scholar
• Fleming C, Morrissey S, Cai Y, Yan J. γδ T cells: unexpected regulators of cancer development and progression. Trends Cancer. 2017;3(8):561–570. doi:10.1016/j.trecan.2017.06.003
   PubMed Web of Science ®Google Scholar
• Zhong W, Liu X, Zhu Z, Li Q, Li K. High levels of Tim-3(+)Foxp3(+)Treg cells in the tumor microenvironment is a prognostic indicator of poor survival of diffuse large B cell lymphoma patients. Int Immunopharmacol. 2021;96:107662. doi:10.1016/j.intimp.2021.107662
   PubMed Web of Science ®Google Scholar
• Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812–3819. doi:10.1182/blood-2006-07-035972
   PubMed Web of Science ®Google Scholar